ADDvise signs a new agreement with Laborie with a total order value of at least MSEK 50 - Regulatory information

05-03-2020   Regulatory press release

ADDvise Group AB (publ)’s subsidiary Sonesta Medical AB signs a new agreement with Laborie Medical Technologies (“Laborie) granting Laborie the right to sell Sonesta Medical’s urology- and gynecology chairs and video fluoroscopy tables (the “Products”) in all countries in the world with an exclusive right to distribution in USA and France, United Kingdom, Ireland, Germany, Belgium, Netherlands, Austria, Switzerland and Luxembourg (the “Exclusive Markets”). The initial term of the agreement is three years. The total value of the orders during the initial term of the agreement is at least MSEK 50.

In accordance with the agreement the parties have agreed upon minimum volumes for the distribution in the Exclusive Markets, entailing that Laborie shall in total order at least 165 Products per year, whereof at least 20 of these units shall be video fluoroscopy tables.

Laborie is a company based in Canada and a leading global developer, manufacturer and marketer of medical technology and consumables used for diagnostic and therapeutic solutions in urology, urogynecology and gastroenterology.

“Laborie is an existing customer to the group. I am proud to get additional order volumes from Laborie which will strengthen our relationship”, says Rikard Akhtarzand, CEO, ADDvise Group AB.

 

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71

rikard.akhtarzand@addvisegroup.se


Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 5 March 2020 at 09.45 CET.
 

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

    

Latest press releases

Interim report 2025, January 1–June 30

Regulatory

In the second quarter of 2025, organic sales adjusted for currency effects increased, driven by steady demand for laboratory equipment and rental of equipment for clinical studies. Operating cash flow improved in the quarter, and EBITA was in line with last year with a stronger margin. Through the new capital structure, ADDvise’s annual interest expenses…

Invitation to presentation of interim report April 1 – June 30, 2025

Non-regulatory

ADDvise Group publishes its interim report April 1 – June 30, 2025 on Thursday, July 17, 2025 at 7.45 am (CET). Media, investors and analysts are invited to attend a webcast and teleconference on the same day at 14:00 (CET). CEO, Staffan Torstensson, and CFO, Johan Irwe, will present the report. Webcast If you wish to…

ADDvise announces that the conditions for early redemption of outstanding secured bonds have been fulfilled

Regulatory

ADDvise Group AB (publ) (“ADDvise” or the “Company”) announced on 14 May 2025 that ADDvise intends to redeem the Company’s outstanding senior secured bonds with ISIN SE0020180271 and ISIN NO0013180786 (the “Early Redemption”). The Early Redemption was conditional upon the entering into of the new secured facilities agreement of the equivalence of SEK 450 million…